FDA
-
-
-
-
-
-
-
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
-
-
-
-
-
-
-
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
-
-
-
-
-
-
-
Atossa Therapeutics (ATOS) Appoints Jonathan Finn to its Board
-
-
-
-
-
-
-
Atossa Therapeutics (ATOS) Approved in Canada to Conduct Phase 2 EVANGELINE Trial
-
-
-
-
-
-
-
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
-
-
-
-
-
-
-
Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
-
-
-
-
-
-
-
Atossa Therapeutics (ATOS) Reports FY22, Provides Corporate Update
-
251,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All